INFY

Share Price: Morgan Stanley flags limited upside on US acquisitions, maintains equal‑weight rating - Check target

Morgan Stanley has taken a cautious view on Infosys’ recently announced US acquisitions of Optimum Healthcare IT and Stratus Global, maintaining an Equal‑weight rating and keeping its target price unchanged at Rs 1,760. While the deals strengthen Infosys’ footprint in the healthcare IT segment, the brokerage believes their near‑term financial impact remains modest. Infosys shares traded mildly higher on Friday morning, with the stock quoting at Rs 1,287.20 as of 9:30 AM gaining Rs 8.10 or 0.63 per cent. Infosys’ plan to acquire Optimum Healthcare IT for about USD 465 million and Stratus for up to USD 95 million is expected to add a combined 1.2 per cent to revenue by FY27, according to Morgan Stanley. However, the brokerage said the transactions are likely to be earnings‑neutral to mildly dilutive, suggesting that strategic benefits may outweigh immediate financial gains, but without materially altering the stock’s risk‑reward profile at current levels.